INNOVIVA, INC. Acquired Finite-lived Intangible Asset, Amount (Deprecated 2013-01-31)
INNOVIVA, INC. (INVA) had Acquired Finite-lived Intangible Asset, Amount (Deprecated 2013-01-31) of $30.00 million as of 2013-06-30, per its 10-Q filed 2013-08-01.
Discontinued › Notes › Intangible Assets
us-gaap:AcquiredFiniteLivedIntangibleAssetAmount · last filed 2013-08-01
- 2013-06-30: Acquired Finite-lived Intangible Asset, Amount (Deprecated 2013-01-31) $30.00M.
| Period end | Acquired Finite-lived Intangible Asset, Amount (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $30.00M 10-Q · filed 2013-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |